METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of drugs aimed at halting bone metastases in prostate cancer
Disease control TerminatedThis study tests a combination of three drugs—radium-223, M3814, and avelumab—in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bone. The goal is to see if the combination can slow cancer growth better than radium-223 alone. The…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Targeted drug shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a drug called M1774 in 20 men with advanced prostate cancer that has a specific genetic change (SPOP mutation) and has stopped responding to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if M1774 c…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis phase 2 trial tests whether combining golimumab (an anti-inflammatory drug) with apalutamide (a hormone blocker) can help men with castration-resistant prostate cancer that has spread. The study enrolled 8 participants and measures PSA reduction and tumor shrinkage. The goal…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New scan could sharpen prostate cancer detection
Diagnosis OngoingThis study tests whether a special PET scan using a tracer called 68Ga-PSMA-11 can find prostate cancer more clearly than standard scans. About 141 men with prostate cancer at different stages will get the scan. The goal is to see if the scan changes how doctors plan treatment, s…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC